Copeland Capital Management LLC Raises Holdings in Novo Nordisk A/S $NVO

Copeland Capital Management LLC grew its position in Novo Nordisk A/S (NYSE:NVO) by 47.3% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 579 shares of the company’s stock after purchasing an additional 186 shares during the quarter. Copeland Capital Management LLC’s holdings in Novo Nordisk A/S were worth $40,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. North Capital Inc. purchased a new stake in shares of Novo Nordisk A/S in the 1st quarter worth $27,000. Stone House Investment Management LLC bought a new position in shares of Novo Nordisk A/S in the 1st quarter worth $30,000. Disciplina Capital Management LLC raised its position in shares of Novo Nordisk A/S by 162.3% in the 1st quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock worth $33,000 after acquiring an additional 297 shares in the last quarter. Spirit of America Management Corp NY bought a new position in shares of Novo Nordisk A/S in the 1st quarter worth $35,000. Finally, Dagco Inc. bought a new position in shares of Novo Nordisk A/S in the 1st quarter worth $35,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Up 1.6%

Shares of NVO stock opened at $59.68 on Friday. The stock’s 50-day simple moving average is $54.92 and its 200-day simple moving average is $63.84. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78. The firm has a market capitalization of $266.45 billion, a PE ratio of 16.39, a P/E/G ratio of 2.25 and a beta of 0.68. Novo Nordisk A/S has a fifty-two week low of $45.05 and a fifty-two week high of $120.56.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, beating analysts’ consensus estimates of $0.93 by $0.04. The business had revenue of $11.69 billion for the quarter, compared to analyst estimates of $77.51 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. Equities analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently disclosed a semi-annual dividend, which was paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th were issued a $0.4119 dividend. The ex-dividend date of this dividend was Monday, August 18th. This represents a dividend yield of 240.0%. Novo Nordisk A/S’s dividend payout ratio is currently 22.53%.

Analysts Set New Price Targets

Several research firms have recently commented on NVO. Sanford C. Bernstein raised Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, September 9th. Berenberg Bank raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Wednesday, September 17th. Wall Street Zen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. Hsbc Global Res raised Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research report on Wednesday. Finally, Barclays reaffirmed an “equal weight” rating on shares of Novo Nordisk A/S in a research report on Wednesday, July 30th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $77.50.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.